Florida Financial Advisors LLC Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Florida Financial Advisors LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 850 shares of the company’s stock after purchasing an additional 179 shares during the quarter. Florida Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $351,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Flossbach Von Storch SE raised its position in shares of IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. William Blair Investment Management LLC increased its stake in IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $113,104,000. Finally, Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after buying an additional 198,404 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IDXX. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $417.66 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $33.85 billion, a P/E ratio of 39.14, a PEG ratio of 3.41 and a beta of 1.39. The company has a 50-day moving average price of $437.36 and a 200-day moving average price of $444.05. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.